| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8812 | LJI-308 Featured | LJI308 is a selective and potent RSK inhibitor. |
|
| DC7711 | Losmapimod Featured | Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
|
| DC10828 | LXH254 Featured | LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
|
| DC8630 | Ralimetinib 2MsOH(LY2228820) Featured | LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC7943 | LYS6K2(LY2584702) tosylate salt Featured | LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
|
| DC8344 | LY3009120 Featured | LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
|
| DC10640 | LY3214996 Featured | LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
|
| DC10751 | M2698 Featured | M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. |
|
| DC7467 | ML-098 Featured | ML-098 is an activator of the GTP-binding protein Rab7 (EC50 = 77.6 nM) that demonstrates selectivity against the related GTPases cdc42, Ras, Rab-2A, and Rac1 (EC50s = 588.8, 346.7, 158.5, and 794.3 nM, respectively). |
|
| DC11829 | MW-150 Featured | MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM |
|
| DC11828 | MW-150 hydrochloride | MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM |
|
| DC9817 | Necrosulfonamide (NSA) Featured | Necrosulfonamide (NSA) is a very specific and potent necrosis inhibitor with an IC50 less than 0.2 uM. |
|
| DC8787 | NQDI-1 Featured | NQDI-1 is a specific inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM) that demonstrates potent selectivity against various serine/threonine and tyrosine protein kinases. |
|
| DC7963 | NSC-23766 free base Featured | NSC 23766 is a specific inhibitor of the binding and activation of RAC GTPase with IC50 of ~50 μM; does not inhibit the closely related targets, Cdc42 or RhoA. |
|
| DC8725 | NSC 23766 Featured | NSC 23766 is a specific inhibitor of the binding and activation of Rac GTPase. |
|
| DC8043 | OTS514 Featured | OTS-514 is a novel TOPK(PDZ binding kinase; PBK) inhibitor. IC50:2.6nM |
|
| DC7723 | OTS964， OTS 964 Featured | OTS964 is a novel TOPK(T–lymphokine-activated killer cell–originated protein kinase) inhibitor. |
|
| DC9681 | Pamapimod（R-1503） Featured | Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor. |
|
| DC10199 | Pan-RAS-IN-1 | Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors. |
|
| DC5100 | PD 98059 Featured | PD 98059 is a selective inhibitor of MEK and blocker of MAPK |
|
| DC1056 | PD0325901 (Mirdametinib) Featured | PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM. |
|
| DC5095 | PD169316 Featured | PD169316 is a potent and selective p38 MAP kinase inhibitor |
|
| DC8744 | PD318088 Featured | PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. |
|
| DC10496 | PF06260933 Featured | PF 06260933 is a potent and selective MAP4K4 inhibitor (IC50 value 3.7 nM for MAP4K4 a.k.a. HGK or ZC1) with suitable PK properties in mouse to be used as a tool in an in vivo model of diabetes, vascular inflammation and atherosclerosis. |
|
| DC8727 | PF-04880594 Featured | PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively. |
|
| DC1071 | Vemurafenib (PLX4032) Featured | PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM. |
|
| DC6301 | PLX-4720 Featured | PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf. |
|
| DC9814 | PLX7904(PB04) Featured | PLX7904(PB04) is a potent and selective paradox-breaker RAF inhibitor. |
|
| DC7370 | AZ-628 Featured | Potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM For c-Raf1, B-RafV600E and wild-type B-Raf, respectively). Displays selectivity For Raf kinases over a panel of 150 other kinases. |
|
| DC5049 | RAF265 (CHIR-265) Featured | RAF265 (CHIR-265) is a highly selective B-Raf and VEGFR2 inhibitor with IC50 of 3-60 nM and EC50 of 30 nM, including B-Raf, C-Raf and mutant B-Raf. |
|
